Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.
Michels
Judith
J
Institut Gustave Roussy, Département de Médecine, Villejuif, France.
Lassau
Nathalie
N
Gross-Goupil
Marine
M
Massard
Christophe
C
Mejean
Arnaud
A
Escudier
Bernard
B
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use*; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D015275:Tumor Lysis Syndrome / Q000000981:diagnostic imaging / Q000209:etiology*; D014463:Ultrasonography
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib